secwatch / observer
8-K filed May 2, 2023, 7:59 PM ET ticker RGEN CIK 0000730272
earnings confidence high sentiment negative materiality 0.75

Repligen Q1 revenue $182.7M, down 12% YoY; cuts full-year guidance on macro headwinds

REPLIGEN CORP

2023-Q1 EPS reported $0.51 revenue$182,660,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REPLIGEN CORP reported first quarter ended March 31, 2023 results: revenue $182.7 million, net income $28.8 million, EPS $0.51. Guidance lowered.

Period
first quarter ended March 31, 2023
Revenue
$182.7 million
Net income
$28.8 million
EPS
$0.51
Guidance
lowered
Result
reported results
Exact text from the filing
REVENUE • Total revenue for the first quarter of 2023 was $182.7 million compared to $206.4 million for the first quarter of 2022, a year-over-year decrease of 12% as reported, and down 9% at constant currency. GROSS PROFIT and GROSS MARGIN • Gross profit (GAAP) for the first quarter of 2023 was $100.8 million compared to $124.0 million for the first quarter of 2022. Adjusted gross profit (non-GAAP) for the first quarter of 2023 was $100.8 million, a decrease of 19% compared to $124.6 million for the first quarter of 2022. • Gross margin (GAAP) for the first quarter of 2023 was 55.2%, compared to 60.1% for the first quarter of 2022. Adjusted gross margin (non-GAAP) for the first quarter was 55.2%, compared to 60.4% in the 2022 period, a year-over-year decrease of approximately 520 basis points. INCOME FROM OPERATIONS • Income from operations (GAAP) for the first quarter of 2023 was $31.3 million, compared to $60.0 million for the first quarter of 2022. Our GAAP income from operations f
View on SEC.gov

Browse all earnings releases →

REPLIGEN CORP filing history →

Source: SEC EDGAR
accession 0001193125-23-131300
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.